Minimal Residual Disease Testing Market Size, Share, Trends & Forecast, 2026–2034
REPORT DETAILS
Minimal Residual Disease Testing Market Summary
The global minimal residual disease (MRD) testing market was valued at USD 2.38 billion in 2025 and is expected to record a CAGR of 13.1% from 2026 to 2034. The increasing number of cancer patients and rising R&D spending drive market expansion. The growing use of next-generation sequencing (NGS) technology also fuels the market growth. Growing technological developments in diagnostics and therapeutics through rising R&D expenditures will boost the market penetration in the coming years.
Market Statistics
Minimal Residual Disease Testing Market Key Takeaways
- In 2025, North America dominated the global market with a 45.7% revenue share. It is supported by strong patient and physician awareness and widespread adoption of advanced screening technologies.
- The Asia Pacific market is expected to witness substantial growth at a 15.2% CAGR during the forecast period due to the rising prevalence of cancer and improving access to advanced diagnostic technologies.
- Europe is expected to witness growth at a 12.4% CAGR during the forecast period, driven by advanced healthcare infrastructure and increasing investments in precision medicine and cancer diagnostics.
- The leukemia segment accounted for the largest market share of 38.6% in 2025. This is due to the high incidence of blood cancers and the increasing investments in leukemia therapeutics.
- Flow cytometry dominated the market with a 34.8% share in 2025, owing to its high sensitivity and broad applicability in MRD testing.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
What Is Minimal Residual Disease Testing?
Minimal residual disease testing (MRD) refers to the small number of cancer cells that remain in a patient's body after treatment. These cells may be too few to detect through standard tests. MRD testing uses highly sensitive methods to find these remaining cancer cells. It is mainly used in blood cancers, such as leukemia and lymphoma. MRD results can help doctors understand treatment response, estimate the risk of cancer returning, and make better decisions about future treatment and patient monitoring.
The development and use of NGS technologies, technological developments in cloud computing and data integration, and the availability of a technologically enhanced framework for healthcare research are all driving the market. Along with this, the expansion of genome mapping programs and the better regulatory & reimbursement environment for NGS-based diagnostic tests drive the minimal residual disease testing market growth throughout the projection period.
How Does MRD Testing Work?
MRD testing involves a particular set of procedures that allow the identification of small amounts of tumor cells in the body after therapy. Firstly, blood or bone marrow is taken for examination. Then the sample undergoes preparation for testing and laboratory analysis. In the laboratory, highly sensitive tests are performed to identify tumor cells that are not detected by standard clinical tests. The laboratory test results determine whether there is MRD, and if possible, quantify it. The doctor then interprets the results and determines the prognosis of the disease and the strategy for monitoring or caring for the patient after treatment.
MRD Testing vs. Traditional Cancer Monitoring
| Criterion | MRD Testing | Traditional Monitoring (Imaging / Standard Biomarkers) |
| Detection sensitivity | 1 cancer cell in 100,000–1,000,000 normal cells | Requires a tumor mass of millions of cells to be detectable |
| Earliest detection point | Months to years before clinical relapse | At or after visible disease progression |
| Sample type | Blood (liquid biopsy) or bone marrow | Imaging (CT/PET/MRI) or standard blood tests |
| Technology used | NGS, flow cytometry, ddPCR, ctDNA assays | Radiology, standard immunoassays, CBC |
| Personalized monitoring | Yes, patient-specific molecular targets | No, population-level thresholds |
| Treatment guidance | Supports dose escalation or de-escalation decisions | Limited, indicates progression but not microscopic residual disease |
| Cancer type coverage | Hematologic malignancies (established); solid tumors (expanding) | Broad but less sensitive |
| Cost | Higher (USD 500–3,000+ per assay) | Lower (established reimbursement pathways) |
| FDA regulatory status | clonoSEQ FDA-cleared (2018); additional assays under review | Fully established and reimbursed |
| Relapse prediction | Predictive (before clinical signs) | Reactive (after clinical signs) |
Source: Polaris Market Research Analysis
Why Healthcare Providers are Investing in MRD Testing
Healthcare providers are beginning to invest more in MRD testing because it empowers them to determine the extent to which a given patient’s cancerous cells have responded to treatment. Additionally, MRD testing is important in identifying minimal levels of disease that would not be detected by conventional tests. Healthcare providers utilize this tool to provide effective and timely interventions for patients whose treatment has not responded positively to conventional treatment.
Source: Polaris Market Research Analysis
Impact of AI on Minimal Residual diseaseTesting Market
- AI can analyze large MRD datasets faster and improve result interpretation.
- It can help identify small cancer-related signals that may be difficult to detect manually.
- AI supports faster analysis of NGS and other complex molecular testing data.
- Machine learning can help predict relapse risk based on MRD results and patient data.
- AI-driven automation may reduce laboratory workload and improve the efficiency of MRD testing.
Market Dynamics
Driver: Rise in Cancer Cases
Global cancer occurrences have significantly increased and are expected to have a major impact on the market growth for treatments for minimal residual illness during the forecast period. According to the American Association for Cancer Research, approx. 18.6 million people who have cured cancer were living in U.S. alone as of January 2025. It is projected that cancer patients who are undergoing cancer therapies favor the growth of the worldwide minimal residual illness market during the forecast period. A shift in the patient's focus toward minimal residual disease is anticipated due to the difficulties of PCR, FISH, & the flow cytometry to enumerate 1 in every 100,000 cells. Patients experience greater treatment accuracy as a result of the use of innovative technology. These factors might effect the overall market worldwide (Source: cancerprogressreport.aacr.org).
Driver: Rising Adoption of Precision Medicine
Minimal residual disease testing is driven by the shift toward precision medicine in healthcare. Doctors and researchers are focusing more on individual treatment paths and how patients respond to therapy. MRD testing enables accurate quantification of cancer cells, which helps identify the best course of treatment for the patient. The insights provided by MRD testing help in making critical treatment decisions based on an individual’s risk category, thereby driving the market growth.
Restraint: High Cost Involved in MRD Testing
MRD testing is a high-cost procedure, which limits the number of patients utilizing it. Most of the tests require sophisticated machines and skilled manpower, thus increasing the cost of testing. Additionally, MRD testing may require serial testing of patients, which could also add up the cost of the procedure. MRD testing may not be accessible in low-income economies, as it requires advanced digital infrastructure to carry out the tests. Small hospitals and laboratories may find it difficult to invest in these technologies due to the high cost of implementation and operation, thereby restraining the industry growth.
Restraint: Lack of Standardization
The lack of standardized operating procedures limits the market growth. Various institutions may implement different testing approaches, which will interfere with the uniform interpretation of results. Moreover, the sensitivity of such tests may differ depending on the equipment used to identify the level of MRD. Therefore, it is important to create standardized protocols for sample preparation and testing procedures.
Restraint: Limited Reimbursement Policies
Limited reimbursement policies for MRD testing challenge its adoption in the healthcare sector. Most insurers have limited coverage for MRD testing, thus making it unaffordable for average citizens. Additionally, reimbursement policies for MRD testing could vary for different cancer types and treatment methodologies. Newer technologies used in MRD testing may lack the required supporting documentation for insurance coverage. Insufficient reimbursement policies may discourage healthcare professionals from adopting MRD testing as the first-line diagnostic tool, thereby restraining the growth.
Opportunity: Liquid Biopsy and Expansion to Other Solid Tumor Types
MRD testing presents a great opportunity for market growth, especially with the expansion of liquid biopsy and the adoption of MRD testing in other solid tumor types. Liquid biopsy could simplify MRD testing and promote its adoption as a regular screening procedure. Unlike traditional tissue biopsies, liquid biopsy involves a simple blood test and can help detect cancer cells circulating in the body. MRD testing is mainly applied in blood cancers. However, researchers are working on developing liquid biopsy-based MRD testing procedures that could work with solid tumor cancer types. The successful commercialization of MRD testing procedures for solid tumor cancer types is expected to fuel the MRD testing market size.
Source: Polaris Market Research Analysis
Segmental Analysis
Detection Target Analysis
In 2025, leukemia dominated the minimal residual disease testing market share of 38.6%. The rising cases of leukemia globally drives the demand for MRD testing leukemia. For instance, according to the American Cancer Society, in 2026, approx. 22,760 cases of chronic lymphocytic leukemia are expected in the U.S. alone. Among these 4,350 deaths due to leukemia are expected in the country. This rise in the cases fuels the demand for early and accurate diagnosis. When the DNA of a single bone marrow cell is altered or mutated, leukemia develops because the cell is unable to mature and perform correctly. Leukemia cells frequently behave abnormally while interacting with white blood cells. According to studies, next-generation sequencing may reduce the prevalence of undiscovered minimal residual illnesses, enabling early care, which is essential for acute lymphocytic leukemia patient survival (Source: cancer.org).
The lymphoma segment is expected to witness growth of CAGR 13.8% during the forecast period. It comprises Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL). NHL presents with a higher opportunity, as it covers numerous disease subtypes and involves a higher utilization of more advanced monitoring approaches. MRD testing provides important information into treatment response and relapse risk. In December 2025, Natera Acquire Foresight Diagnostics for USD 450 million. Foresight Diagnostics is a Stanford University spinout that develops blood tests for tracking minimal residual disease (Source: fiercebiotech.com).
Multiple myeloma is expected to witness growth of CAGR 12.9% during the forecast period, as it is one of the key applications of MRD testing. MRD negativity, which means the absence of cancer cells in the body after therapy, is increasingly used as an important indicator of treatment response. Moreover, it is a powerful clinical trial endpoint that can speed up the study of new treatments. The FDA Oncologic Drugs Advisory Committee (ODAC) discussions have fueled the development and adoption of MRD as an endpoint to help in drug discovery. All these factors are driving the multiple myeloma MRD testing segment growth.
Solid tumors is expected to witness growth of CAGR 15.4% during the forecast period, as it represents a major future growth opportunity for the MRD market. ctDNA testing, which detects tumor-related DNA fragments in blood, is supporting this expansion. Liquid biopsy allows repeated monitoring through a simple blood sample and may reduce the need for invasive procedures. Companies are increasingly developing MRD tests for colorectal, lung, breast, and other solid tumors, thereby driving the segment growth.
Test Technique Analysis
Flow cytometry dominated the minimal residual disease testing market share in 2025 with a 34.8% share. Flow cytometry MRD market growth is driven by its excellent sensitivity and broad applicability. The clinical care of individuals with acute leukemia places a growing emphasis on minimal residual disease testing. Among the technologies for monitoring MRD, flow cytometry has the most potential for clinical usage due to its ease of use and accessibility. Numerous investigations have supported the validity of the method by demonstrating high relationships between MRD levels measured by flow cytometry during clinical remission and treatment results. Identification of the immune-phenotypic combinations which are expressed in the leukemic cells but not in the healthy hematopoietic cells forms the basis for the flow cytometry MRD detection. The specificity of the immunophenotypes employed to identify the leukemic cells and the quantity of study cells determine the sensitivity of the method. A cancer cell can be found with this technology out of 10,000 to 100,000 healthy bone-marrow cells, depending on the flow cytometry setting and results can be available in less time than a day.
The PCR segment is expected to witness growth of CAGR 12.6% during the forecast period driven by its established use, high sensitivity, and relatively faster turnaround time. The technique can detect specific genetic markers associated with cancer cells. High levels of acceptance in the clinical laboratory fuel the segment growth. Additionally, PCR tests are relatively easy to adopt in laboratory settings compared to newer technologies. Increased demand for the accurate monitoring of treatment response and early detection of relapse is expected to drive the adoption of the technique, thereby driving the segment growth.
NGS segment is expected to register a CAGR of 16.2% during the forecast period, driven by its ability to detect multiple genetic markers, including its high sensitivity. This enable in-depth analysis of residual cancer cells. The expansion of the personalized medicine biomarkers market is expected to increase the demand for NGS-based MRD testing. Additionally, the continuous advancements in sequencing technologies are anticipated to shorten the turnaround time and improve accuracy. The growing use of NGS technology in clinical research and in clinical trials to monitor disease progression is further driving the growth.
| Technology | 2025 Market Share | Key Advantage | Key Limitation | Primary Application |
| Flow Cytometry | largest | Rapid turnaround; widely available; multi-marker simultaneous analysis | Lower sensitivity vs. NGS; requires fresh samples | Leukemia, lymphoma remission monitoring |
| PCR (qPCR / ddPCR) | Fastest-growing | Exceptional sensitivity; precise quantification; rapid results | Requires known target sequence; less suitable for novel mutations | ALL, CLL; specific fusion-gene monitoring |
| Next-Generation Sequencing (NGS) | Fastest-growing | Ultra-sensitive; genome-wide; personalized tumor-informed assays; multi-cancer | Higher cost; longer turnaround; bioinformatics expertise required | Solid tumors, hematologic malignancies, clinical trials |
| Others (FISH, Cytogenetics) | Declining share | Established; morphological context | Lower sensitivity; labor-intensive | Diagnostic confirmation; relapse verification |
Source: Polaris Market Research Analysis
End User Analysis
The hospitals & specialty clinics segment dominated with largest minimal residual disease testing market of 50.6% in 2025 driven by the rising adoption of MRD testing in the broader treatment and surveillance of patients. These healthcare facilities deal with a large patient base of cancer patients and drives the demand for MRD testing to monitor treatment response. Moreover, MRD testing helps in making timely treatment and support treatment decisions for the patient. Personalized care and treatment are encouraging the use of MRD testing. Additionally, the presence of specialized healthcare professionals and infrastructure for treatment also further this segment’s growth.
The laboratory centers segment is expected to witness growth of CAGR 14.7% during the forecast period driven by the rising need for third-party testing for specialized and sensitive MRD testing procedures. A significant number of hospitals choose to outsource their MRD testing procedures to specialized labs equipped with advanced technology and expertise. The segment is also driven by the high investments in technologically advanced methods such as PCR and NGS. Moreover, compared to hospitals, diagnostic labs have an advantage of higher scalability in sample processing. The need in standardized, faster, and higher-volume testing procedures have further fuel the demand, thereby driving the segment growth.
Key Areas of Minimal Residual Disease Testing Market
Bioinformatics in MRD Analysis
Bioinformatics plays a important role in analyzing the complicated MRD data generated from next-generation sequencing MRD tests. The field employs various software and data analysis tools that help in detecting subtle genetic signals, which may indicate the presence of cancerous cells. Bioinformatics can be used to design better analytical tools that can help in processing and analyzing the data generated from these tests. Moreover, It can be used to ensure that patient samples are analyzed using similar procedures to ensure consistency in results.
For instance, in the ZUMA-7 trial, genomic profiling of circulating tumor DNA (ctDNA) was used to detect MRD in relapsed/refractory large B-cell lymphoma patients. As per the analysis, MRD negativity had high concordance with PET-based complete remission overall. It helps validate ctDNA-based bioinformatics as a viable response-assessment tool. (Source: pmc.ncbi.nlm.nih.gov)
MRD in Immunotherapy & CAR-T Monitoring
MRD testing is expected to have a major role in supporting the use of immunotherapy and CAR-T monitoring. The current application of these treatments is to ensure that cancerous cells are segregated from healthy cells in affected patients. MRD testing data can be used to monitor the degree to which cancerous cells in a given patient have responded to therapies designed to target them. This information would be important role in determining the course of immunotherapy treatment and ensuring that healthy cells are not adversely affected.
Stem Cell Transplant Monitoring
MRD testing is important in both the pre- and post-transplant stages of stem cell transplant. During the former, it can support clinical professionals in determining the extent to which a given patient’s cancer has been eradicated by the transplant procedure. The results of MRD testing can also help in determining the appropriate timing and dose of post-transplant chemotherapy. Moreover, the application of MRD testing in monitoring blood cancer patients during the post-remission phase can help in informing early intervention strategies in detecting disease relapse.
The EMN02/HO95 multiple myeloma trial (via its NMSG flow-MRD substudy) tracked MRD in patients in complete remission following autologous stem-cell transplant. Increasing MRD levels preceded biochemically assessed changes. This made flow-MRD an early indicator of relapse ahead of conventional markers.
Clinical Trials & Drug Development Applications
MRD testing is gaining importance in clinical trials and drug development. This form of analysis can be used by clinical researchers to determine the efficacy of pharmaceuticals in clearing cancerous cells from the body. MRD testing information are important for ensuring that appropriate measures are applied when monitoring patient response to treatment. The data generated by this type of testing can be used to help pharmaceutical companies submit applications for FDA approval since it is used to indicate treatment efficacy at an early stage of treatment. FDA approval of MRD testing as a surrogate endpoint in various forms of blood cancers would be a significant boost to its adoption in oncology drug discovery and development processes.
Role of MRD in Precision Oncology
MRD testing supports precision oncology by providing detailed information about a patient's response to treatment. Information generated from this type of cancer analysis are used to indicate the general treatment outlook of patients based on their response to treatment. Instead of adopting a uniform approach to cancer treatment, medical professionals use MRD testing information to help guide the treatment strategy for each patient. This method is used to inform treatment follow-up and monitoring based on the risk levels that apply to a given patient.
Source: Polaris Market Research Analysis
Regional Analysis
North America Minimal Residual Disease Testing Market Assessment
North America dominated the market with the largest share of 45.7% in 2025 due to rising healthcare affordability in the U.S. North America is controlling the minimal residual disease diagnostics and testing industry. Due to a high level of patient and physician awareness of the advantages associated with screening, the U.S. and Canada are the two main markets for cancer screening in North America. Additionally, a number of projects are being implemented to offer MRD testing in the area. For instance, in January 2025, Adaptive Biotechnologies and NeoGenomics announced a partnership to improve the minimal residual disease (MRD) monitoring treatment for blood cancers patients. Thereby driving the region growth (Source: ir.neogenomics.com).
Asia Pacific Minimal Residual Disease Testing Market Insights
The Asia Pacific market is expected to witness significant growth of CAGR of 15.2% during the forecast period due to the rise in disease burden. The rise in disease incidence of hematological cancers such as lumphoma and leukemia is due to the changing lifestyles, aging populations, and improved diagnostic capabilities. The prevalence of this disease creates an expanding number of cases which requires proper monitoring, contributing to the demand for refined MRD testing solutions for treatment decisions and also for long term outcomes.
India's Molecular Diagnostics Ecosystem
MRD India market is expected to witness growth of 16.8% CAGR during the forecast period driven by the rapid development of the country’s diagnostic infrastructure and the rise of genomic testing capabilities in the country. The growing number of hospitals offering advanced molecular technologies, including PCR and NGS, contributes to the demand for MRD testing. Development of private healthcare chains and networks of specialized cancer hospitals further drives growth. India’s large biotechnology sector and R&D capabilities and the presence of a constant supply of skilled labor allow for the development of homegrown diagnostic tests, thereby driving the growth in India.
Europe Minimal Residual Disease Testing Market insights
Europe is expected to register growth of CAGR 12.4% due to advance healthcare infrastructure development and the presence of specialized cancer hospitals and research centers offering innovative diagnostic approaches, including MRD testing. The growth is further driven by the growing adoption of precision medicine and need for comprehensive treatment monitoring solutions. Moreover, there is an emerging trend across Europe for clinical cancer research and collaborative networks for innovative diagnostic technology development and implementation. The growing number of clinical studies and trials incorporating MRD testing are further driving growth in the region.
Latin America Minimal Residual Disease Testing Market insights
The Latin American MRD market is expected to witness growth of 12.2% CAGR driven by the ongoing improvement in the regional healthcare ecosystem and the increasing presence of private medical institutions offering advance diagnostic technologies. Across the region, major healthcare players are partnering with local and international firms to launch innovative cancer diagnostic solutions to the local market. The rising awareness of precision medicine among healthcare professionals, as well as the rising investments in diagnostic lab infrastructure are further driving the market.
Middle East & Africa Minimal Residual Disease Testing Market insights
The Middle East and Africa MRD market is anticipated to register growth of 11.6% CAGR during the forecast period driven by increasing investment in healthcare modernization and specialized cancer treatment facilities. Countries in the Gulf region are expanding molecular diagnostics and precision medicine programs. Government healthcare investments and partnerships with international diagnostic companies are improving access to advanced testing. The development of specialized laboratories is also supporting market growth. In Africa, improving healthcare infrastructure and laboratory capacity create long-term opportunities. Growing focus on advanced cancer monitoring and personalized treatment is expected to support the gradual adoption of MRD testing.
Source: Polaris Market Research Analysis
Competitive Landscape
The MRD market is competitive, with diagnostic companies, genomics firms, and specialized laboratories competing through advanced testing technologies. Key players include Natera, Adaptive Biotechnologies clonoSEQ, Guardant Health, Roche, QIAGEN, Sysmex, and NeoGenomics. Companies focus on improving test accuracy, expanding into solid tumors, and developing liquid biopsy MRD testing solutions. Strategic partnerships with hospitals, pharmaceutical companies, and research institutions are also important. Larger companies benefit from broad laboratory networks, while specialized players compete through innovative NGS, PCR, and personalized MRD testing platforms.
Some of the major players
- Adaptive Biotechnologies
- ArcherDX
- ARUP Laboratories
- Asuragen
- Bio-Rad Laboratories
- Cergentis
- F. Hoffmann-La Roche Ltd.
- Genetron Health
- GRAIL, LLC
- Guardant Health
- ICON plc (MolecularMD
- Inivata
- Invivoscribe
- Mission Bio
- Natera
- NeoGenomics Laboratories
- Opko Health
- QIAGEN
- Quest Diagnostics.
- Sysmex Corporation
Key Players Positioning table
| Company | Headquarters | Key MRD Product / Platform | Primary Technology | Cancer Focus |
| Adaptive Biotechnologies | USA | clonoSEQ (FDA-cleared) | NGS (immunosequencing) | Multiple myeloma, ALL, CLL, DLBCL |
| Natera, Inc. | USA | Natera Signatera MRD test; Signatera Genome; Signatera ctDNA | Tumor-informed NGS / ctDNA | Solid tumors; hematologic |
| Guardant Health | USA | Guardant Reveal Liquid Biopsy | ctDNA / liquid biopsy | Solid tumors; colorectal, breast |
| F. Hoffmann-La Roche Ltd. | Switzerland | Digital LightCycler; cobas platforms | Digital PCR, NGS | Broad oncology |
| Sysmex Corporation | Japan | SCIS / MACS flow systems | Flow cytometry | Leukemia Therapeutics, lymphoma |
| Bio-Rad Laboratories | USA | Droplet Digital PCR (ddPCR) | Digital PCR | Hematologic malignancies |
| NeoGenomics Laboratories | USA | COMPASS; integrated with clonoSEQ | Flow cytometry, NGS | Blood cancers |
| Invivoscribe, Inc. | USA | LymphoTrack assays | NGS, PCR | Lymphoma, leukemia |
| Quest Diagnostics | USA | Haystack MRD ctDNA test (NY-approved Jun 2026) | ctDNA liquid biopsy Cancer | Solid tumors |
| QIAGEN | Netherlands | therascreen kits; MRD companion diagnostics | PCR / NGS reagents | Broad |
| Mission Bio | USA | Tapestri single-cell DNA | Single-cell NGS | AML, MDS |
| Cergentis B.V. | Netherlands | TLA-seq (targeted locus amplification) | NGS | Hematologic |
| ARUP Laboratories | USA | Reference lab MRD panels | Flow cytometry, PCR | Leukemia, lymphoma |
| Inivata (Roche subsidiary) | USA/UK | InVision ctDNA platform | ctDNA NGS | Solid tumors |
| ArcherDX (Invitae) | USA | Archer FusionPlex; Reveal ctDNA | NGS | Solid tumors, hematologic |
Source: Polaris Market Research Analysis
Recent Developments in the Minimal Residual Disease Industry
- May 2026: Illumina launched its first distributed whole-genome sequencing solution for MRD research, enabling faster and highly sensitive cancer detection. The new workflow supports solid tumors and blood cancers, expands access to MRD research, and strengthens Illumina’s growing oncology portfolio. (Source: illumina.com)
- September 2026: MedGenome launched OncoTrack MRD, a personalized and ultrasensitive blood-based test for detecting MRD. The test used patient-specific tumor signals to identify potential cancer recurrence earlier, support treatment decisions, and expand access to advanced precision oncology diagnostics across India. (Source: healthcareexecutive.in)
- February 2021: QIAGEN expanded its oncology diagnostics portfolio through strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. The collaborations advanced MRD testing for solid tumors and lymphoma, supporting decentralized, non-invasive cancer monitoring and personalized treatment decisions in clinical trials. (Source: qiagen.com)
Future Outlook
The future outlook for the MRD market growth is positive due to the advancement of the NGS, liquid biopsy, and ctDNA-based technologies. The market is expected to grow beyond blood cancers and enter into the realm of solid tumors such as lung, breast and colorectal cancer. MRD testing is likely to become more involved in clinical trials, drug discovery, and personalized treatment decisions. Increased standardization and improved reimbursement are likely to propel adoption of MRD testing.
Minimal Residual Disease Testing Market Segmentation
By Detection Type Outlook (USD Billion, 2021–2034)
- Lymphoma
- Leukemia
- Solid Tumors
- Multiple Myeloma
- Others
By Test Technique Outlook (USD Billion, 2021–2034)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Others
By End User Outlook (USD Billion, 2021–2034)
- Hospitals and Specialty Clinics
- Laboratory Centres
By Regional Outlook (USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Minimal Residual Disease Testing Market Report Scope
| Report Attributes | Details |
| Market size in 2025 | USD 2.38 billion |
| Market size in 2026 | USD 2.69 billion |
| Revenue forecast in 2034 | USD 7.20 billion |
| CAGR | 13.1% from 2026 - 2034 |
| Base year | 2025 |
| Historical data | 2021 - 2024 |
| Forecast period | 2026-20344 |
| Quantitative units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Segments covered |
|
| Regional scope |
|
| Key companies | Minimal Residual Market Analysis (2025) Company profiles/industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments. |
|
| PDF + Excel |
Source: Polaris Market Research Analysis
Minimal Residual Disease Testing Market FAQ's
key segments are detection target, test technique, end-user and region.
Minimal Residual Disease Testing Market Size Worth USD 7.20 Billion By 2034.
The global minimal residual disease testing market expected to grow at a CAGR of 13.1% during the forecast period.
North America is leading the global market share 45.7% in 2025.
key driving factors are Increasing Prevalence Of Cancer and Growing Investment For Research.
MRD testing is more sensitive and can detect very small amounts of remaining disease that standard tests may miss.
Key technologies include PCR, NGS, and flow cytometry, depending on the cancer type and testing needs.
Key drivers include precision medicine, early relapse detection, technology advancements, and growing use in clinical trials.
High testing costs, lack of standardization, and limited reimbursement remain key market challenges.
Download Sample Report of Minimal Residual Disease Testing Market
Please fill out the form to request a customized copy of the research report.
